Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions

References

• Henderson RC, Lark RK, Gurka MJ, Worley G, Fung EB, Conaway M, Stallings VA, Stevenson RD. Bone density and metabolism in children and adolescents with moderate to severe cerebral palsy. Pediatrics 2002; 110: e5
   PubMed Web of Science ®Google Scholar
• Khoury DJ, Szalay EA. Bone mineral density correlation with fractures in nonambulatory pediatric patients. Journal Pediatric Orthopedics 2007; 27: 562–566
   PubMedGoogle Scholar
• King W, Levin R, Schmidt R, Oestreich A, Heubi JE. Prevalence of reduced bone mass in children and adults with spastic quadriplegia. Developmental Medicine and Child Neurology 2003; 45: 12–16
   PubMed Web of Science ®Google Scholar
• Roberts D, Lee W, Cuneo RC, Wittmann J, Ward G, Flatman R, et al. Longitudinal study of bone turnover after acute spinal cord injury. Journal of Clinical Endocrinology Metabolism 1998; 83: 415–422
   PubMed Web of Science ®Google Scholar
• Nance PW, Schryvers O, Leslie W, Ludwig S, Krahn J, Uebelhart D. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Archives of Physical Medicine and Rehabilitation 1999; 80: 243–251
   PubMed Web of Science ®Google Scholar
• Szollar SM, Martin EM, Sartoris DJ, Parthemore JG, Deftos LJ. Bone mineral density and indexes of bone metabolism in spinal cord injury. American Journal of Physical Medicine and Rehabilitation. 1998; 77: 28–35
   PubMed Web of Science ®Google Scholar
• Kannisto M, Alaranta H, Merikanto J, Kroger H, Karkkainen J. Bone mineral status after pediatric spinal cord injury. Spinal Cord 1998; 36: 641–646
   PubMed Web of Science ®Google Scholar
• Fewtrell MS, Prentice A, Jones SC, Bishop NJ, Stirling D, Buffenstein R, Lunt M, Cole TJ, Lucas A. Bone mineralization and turnover in preterm infants at 8-12 years of age: The effect of early diet. Journal of Bone Mineral Research 1999; 14: 810–820
   PubMed Web of Science ®Google Scholar
• Henderson RC, Kairalla J, Abbas A, Stevenson RD. Predicting low bone density in children and young adults with quadriplegic cerebral palsy. Developmental Medicine and Child Neurology 2004; 46: 416–419
   PubMed Web of Science ®Google Scholar
• Henderson RC, Lark RK, Kecskemethy HH, Miller F, Harcke HT, Bachrach SJ. Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: A randomized, placebo-controlled clinical trial. Journal of Pediatrics 2002; 141: 644–651
   PubMed Web of Science ®Google Scholar
• Plotkin H, Coughlin S, Kreikemeier R, Heldt K, Bruzoni M, Lerner G. Low doses of pamidronate to treat osteopenia in children with severe cerebral palsy: A pilot study. Developmental Medicine and Child Neurology 2006; 48: 709–712
   PubMedGoogle Scholar
• Bachrach SJ, Kecskemethy HH, Harcke HT, Lark RK, Miller F, Henderson RC. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy. Journal of Clinical Densitometry 2006; 9: 167–174
   PubMedGoogle Scholar
• Houlihan CM, O’Donnell M, Conaway M, Stevenson RD. Bodily pain and health-related quality of life in children with cerebral palsy. Developmental Medicine and Child Neurology 2004; 46: 305–310
   PubMed Web of Science ®Google Scholar
• Msall ME, DiGaudio K, Duffy LC, LaForest S, Braun S, Granger CV, WeeFIM. Normative sample of an instrument for tracking functional independence in children. Clinical Pediatrics (Philadelphia) 1994; 33: 431–438
   PubMed Web of Science ®Google Scholar
• Msall ME, DiGaudio K, Rogers BT, LaForest S, Catanzaro ML, Campbell J, Wilczenski F, Duffy LC. The Functional Independence Measure for Children (WeeFIM): Conceptual basis and pilot use in children with developmental disabilities. Clinical Pediatrics 1994; 33: 421–430
   PubMed Web of Science ®Google Scholar
• Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Developmental Medicine and Child Neurology 1997; 39: 214–223
   PubMed Web of Science ®Google Scholar
• Lewiecki EM, Miller PD. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opinion in Drug Safety 2007; 6: 663–672
   PubMed Web of Science ®Google Scholar
• Stratton JD, Warwicker P. Relapse of nephrotic syndrome triggered by biphosphonates. Nephrology Dialysis Transplant 2002; 17: 1856–1857
   PubMedGoogle Scholar
• Szeto CC, Chow KM. Nephrotoxicity related to new therapeutic compounds. Renal Failure 2005; 27: 329–333
   PubMed Web of Science ®Google Scholar
• Conte P, Guarneri V. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist 2004; 9(Suppl 4)28–37
   PubMed Web of Science ®Google Scholar
• Henderson R. Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children. Developmental Medicine and Child Neurology 2006; 48: 708
   PubMedGoogle Scholar